Changing the Paradigm for the Treatment and Development of New Therapies for FSGS.
about
Focal Segmental Glomerulosclerosis.Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET).An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis.NephCure Accelerating Cures Institute: A Multidisciplinary Consortium to Improve Care for Nephrotic Syndrome.
P2860
Changing the Paradigm for the Treatment and Development of New Therapies for FSGS.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Changing the Paradigm for the Treatment and Development of New Therapies for FSGS.
@ast
Changing the Paradigm for the Treatment and Development of New Therapies for FSGS.
@en
type
label
Changing the Paradigm for the Treatment and Development of New Therapies for FSGS.
@ast
Changing the Paradigm for the Treatment and Development of New Therapies for FSGS.
@en
prefLabel
Changing the Paradigm for the Treatment and Development of New Therapies for FSGS.
@ast
Changing the Paradigm for the Treatment and Development of New Therapies for FSGS.
@en
P2093
P2860
P356
P1476
Changing the Paradigm for the Treatment and Development of New Therapies for FSGS.
@en
P2093
Cathie Spino
David T Selewski
Debbie S Gipson
Jonathan Troost
Jordan S Jahnke
Susan Massengill
P2860
P356
10.3389/FPED.2016.00025
P577
2016-03-23T00:00:00Z